Can plasma Epstein-Barr virus DNA levels be used to monitor nasopharyngeal carcinoma progression?
Farrell
Paul J
PJ
Department of Virology, Imperial College London, UK. p.farrell@imperial.ac.uk
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000821:virology*; D016022:Case-Control Studies; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004279:DNA, Viral / Q000097:blood*; D018450:Disease Progression; D005472:Fluorouracil / Q000008:administration & dosage; D005838:Genotype; D004854:Herpesvirus 4, Human / Q000235:genetics*; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000821:virology*; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D016133:Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D016019:Survival Analysis
D015415:Biomarkers; D004279:DNA, Viral; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil